Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) — Cash Flow-to-Debt Ratio
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of CN¥502.01 Million could theoretically repay 0% of its total liabilities (CN¥3.56 Billion) in one year. See 603707 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Nanjing King-friend Biochemical Pharmaceutical Co Ltd across 13 annual periods. Also explore net asset growth rate of Nanjing King-friend Biochemical Pharmace to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
Year-by-year debt coverage analysis for Nanjing King-friend Biochemical Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Nanjing King-friend Biochemical Pharmace stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.34x | CN¥1.18 Billion | CN¥3.44 Billion | ▼ -30.9% |
| 2024 | 0.50x | CN¥1.50 Billion | CN¥3.02 Billion | ▲ +14.3% |
| 2023 | 0.43x | CN¥1.62 Billion | CN¥3.73 Billion | ▲ +180.5% |
| 2022 | 0.15x | CN¥595.45 Million | CN¥3.84 Billion | ▼ -36.2% |
| 2021 | 0.24x | CN¥683.63 Million | CN¥2.81 Billion | ▲ +270.7% |
| 2020 | -0.14x | CN¥-565.85 Million | CN¥3.98 Billion | ▲ +64.9% |
| 2019 | -0.41x | CN¥-841.38 Million | CN¥2.07 Billion | ▼ -738.1% |
| 2018 | 0.06x | CN¥62.37 Million | CN¥981.21 Million | ▲ +117.4% |
| 2017 | -0.37x | CN¥-234.59 Million | CN¥642.50 Million | ▲ +73.5% |
| 2016 | -1.38x | CN¥-286.79 Million | CN¥208.09 Million | ▼ -305.5% |
| 2015 | 0.67x | CN¥137.28 Million | CN¥204.72 Million | ▲ +90.7% |
| 2014 | 0.35x | CN¥178.74 Million | CN¥508.26 Million | ▼ -74.8% |
| 2013 | 1.40x | CN¥193.91 Million | CN¥138.91 Million | — |